Abstract
The analytical algorithm of Lynch syndrome (LS) is increasingly complex. BRAF V600E mutation and MLH1 promoter hypermethylation have been proposed as a screening tool for the identification of LS. The aim of this study was to assess the clinical usefulness and cost-effectiveness of both somatic alterations to improve the yield of the diagnostic algorithm of LS. A total of 122 colorectal tumors from individuals with family history of colorectal cancer that showed microsatellite instability and/or loss of mismatch repair (MMR) protein expression were studied. MMR germline mutations were detected in 57 cases (40 MLH1, 15 MSH2 and 2 MSH6). BRAF V600E mutation was assessed by single-nucleotide primer extension. MLH1 promoter hypermethylation was assessed by methylation-specific multiplex ligation-dependent probe amplification in a subset of 71 cases with loss of MLH1 protein. A decision model was developed to estimate the incremental costs of alternative case-finding methods for detecting MLH1 mutation carriers. One-way sensitivity analysis was performed to assess robustness of estimations. Sensitivity of the absence of BRAF mutations for depiction of LS patients was 96% (23/24) and specificity was 28% (13/47). Specificity of MLH1 promoter hypermethylation for depiction of sporadic tumors was 66% (31/47) and sensitivity of 96% (23/24). The cost per additional mutation detected when using hypermethylation analysis was lower when compared with BRAF study and germinal MLH1 mutation study. Somatic hypermethylation of MLH1 is an accurate and cost-effective pre-screening method in the selection of patients that are candidates for MLH1 germline analysis when LS is suspected and MLH1 protein expression is absent.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Lynch HT, Krush AJ : Cancer family ‘G’ revisited: 1895-1970. Cancer 1971; 27: 1505–1511.
Mecklin JP, Jarvinen HJ : Tumor spectrum in cancer family syndrome (hereditary nonpolyposis colorectal cancer). Cancer 1991; 68: 1109–1112.
Marra G, Boland CR : Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst 1995; 87: 1114–1125.
Peltomaki P, Vasen HF : Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 1997; 113: 1146–1158.
Wu Y, Berends MJ, Sijmons RH et al: A role for MLH3 in hereditary nonpolyposis colorectal cancer. Nat Genet 2001; 29: 137–138.
Aaltonen LA, Salovaara R, Kristo P et al: Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998; 338: 1481–1487.
Loukola A, Eklin K, Laiho P et al: Microsatellite marker analysis in screening for hereditary nonpolyposis colorectal cancer (HNPCC). Cancer Res 2001; 61: 4545–4549.
Hampel H, Frankel WL, Martin E et al: Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005; 352: 1851–1860.
Lindor NM, Burgart LJ, Leontovich O et al: Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002; 20: 1043–1048.
Deng G, Bell I, Crawley S et al: BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004; 10: 191–195.
Domingo E, Laiho P, Ollikainen M et al: BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 2004; 41: 664–668.
Domingo E, Niessen RC, Oliveira C et al: BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene 2005; 24: 3995–3998.
Lubomierski N, Plotz G, Wormek M et al: BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. Cancer 2005; 104: 952–961.
McGivern A, Wynter CV, Whitehall VL et al: Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer 2004; 3: 101–107.
Wang L, Cunningham JM, Winters JL et al: BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003; 63: 5209–5212.
Bessa X, Balleste B, Andreu M et al: A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening. Clin Gastroenterol Hepatol 2008; 6: 206–214.
Domingo E, Espin E, Armengol M et al: Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. Genes Chromosomes Cancer 2004; 39: 138–142.
Julie C, Tresallet C, Brouquet A et al: Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening. Am J Gastroenterol 2008; 103: 2825–2835, quiz 2836.
Lagerstedt Robinson K, Liu T, Vandrovcova J et al: Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. J Natl Cancer Inst 2007; 99: 291–299.
Loughrey MB, Waring PM, Tan A et al: Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam Cancer 2007; 6: 301–310.
Perez-Carbonell L, Alenda C, Paya A et al: Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome. J Mol Diagn 2010; 12: 498–504.
Walsh MD, Buchanan DD, Walters R et al: Analysis of families with Lynch syndrome complicated by advanced serrated neoplasia: the importance of pathology review and pedigree analysis. Fam Cancer 2009; 8: 313–323.
Bettstetter M, Dechant S, Ruemmele P et al: Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR. Clin Cancer Res 2007; 13: 3221–3228.
Cunningham JM, Christensen ER, Tester DJ et al: Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998; 58: 3455–3460.
Kuismanen SA, Holmberg MT, Salovaara R, de la Chapelle A, Peltomaki P : Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. Am J Pathol 2000; 156: 1773–1779.
Alemayehu A, Sebova K, Fridrichova I : Redundant DNA methylation in colorectal cancers of Lynch-syndrome patients. Genes Chromosomes Cancer 2008; 47: 906–914.
Nagasaka T, Sasamoto H, Notohara K et al: Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol 2004; 22: 4584–4594.
Rahner N, Friedrichs N, Steinke V et al: Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome. J Pathol 2008; 214: 10–16.
Bonis PA, Trikalinos TA, Chung M et al: Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications. Evid Rep Technol Assess (Full Rep) 2007; 1–180.
Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009; 11: 35–41.
Motulsky AG : Screening for genetic diseases. N Engl J Med 1997; 336: 1314–1316.
Landi S, Moreno V, Gioia-Patricola L et al: Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res 2003; 63: 3560–3566.
Berkhout M, Nagtegaal ID, Cornelissen SJ et al: Chromosomal and methylation alterations in sporadic and familial adenomatous polyposis-related duodenal carcinomas. Mod Pathol 2007; 20: 1253–1262.
Jeuken JW, Cornelissen SJ, Vriezen M et al: MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 2007; 87: 1055–1065.
Azuara D, Rodriguez-Moranta F, de Oca J et al: Novel methylation panel for the early detection of colorectal tumors in stool DNA. Clin Colorectal Cancer 2010; 9: 168–176.
Deng G, Chen A, Hong J, Chae HS, Kim YS : Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res 1999; 59: 2029–2033.
Borras E, Pineda M, Blanco I et al: MLH1 founder mutations with moderate penetrance in Spanish Lynch syndrome families. Cancer Res 2010; 70: 7379–7391.
Rozek LS, Herron CM, Greenson JK et al: Smoking, gender, and ethnicity predict somatic BRAF mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2010; 19: 838–843.
Bouzourene H, Hutter P, Losi L, Martin P, Benhattar J : Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation. Fam Cancer 2010; 9: 167–172.
Hitchins MP, Ward RL : Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary non-polyposis colorectal cancer. J Med Genet 2009; 46: 793–802.
Dong SM, Lee EJ, Jeon ES, Park CK, Kim KM : Progressive methylation during the serrated neoplasia pathway of the colorectum. Mod Pathol 2005; 18: 170–178.
Kambara T, Simms LA, Whitehall VL et al: BRAF mutation is associated with DNA methyation in serrated polyps and cancers of the colorectum. Gut 2004; 53: 1137–1144.
Acknowledgements
This work was supported by grants from Ministerio de Ciencia e Innovación (SAF 06-06084; 09-07319), Fundació Gastroenterologia Dr Francisco Vilardell (F05-01), Ministerio de Educación y Ciencia Spanish Networks RTICCC (RD06/0020/1050, 1051), Acción en Cáncer (Instituto de Salud Carlos III) and Fundación Científica de la AECC and National Cancer Institute P30 CA46592.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on European Journal of Human Genetics website
Supplementary information
Rights and permissions
About this article
Cite this article
Gausachs, M., Mur, P., Corral, J. et al. MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study. Eur J Hum Genet 20, 762–768 (2012). https://doi.org/10.1038/ejhg.2011.277
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ejhg.2011.277
Keywords
This article is cited by
-
Implication of DNA repair genes in Lynch-like syndrome
Familial Cancer (2019)
-
Highly sensitive MLH1 methylation analysis in blood identifies a cancer patient with low-level mosaic MLH1 epimutation
Clinical Epigenetics (2019)
-
Personalized medicine in colorectal cancer diagnosis and treatment: a systematic review of health economic evaluations
Cost Effectiveness and Resource Allocation (2018)
-
BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers
Breast Cancer Research (2017)
-
Precision medicine in heritable cancer: when somatic tumour testing and germline mutations meet
npj Genomic Medicine (2016)
